Phase 2 N=30 TVEC and Preop Radiation for Sarcoma (4 ml Dose)
Soft Tissue Sarcoma
Primary: Phase 1b: Number of Subjects With Dose Limiting Toxicities (DLTs) — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=396 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
Schizophrenia
Primary: Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score — 88.3; 88.1; -15.3; -13.4 score on a scale — p=0.0940
Phase 4 N=10 Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans
PTSD
Primary: PTSD Symptom Severity — 31.5; 23 score on a scale
N/A N=34 Effects of an Apple Extract on Glycaemia: The GLU-Pomme Study
Prevention of Hyperglycaemia
Primary: Postprandial Glycaemia — 11.3; 15.2; 17.8; 27.1 mmol/L*min
Phase 1 N=5 Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Atopic Dermatitis
Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance
Phase 2 N=313 Abatacept as GVHD Prophylaxis Phase 2
Graft vs Host Disease · Malignancy
Primary: Percentage of Participants With Cumulative Incidence of Severe aGVHD at Day +100 Post-transplant — 6.8; 14.8; 2.2; 30.2 percentage of participants
Phase 2 N=171 Imaging Regional Lung Defect Severity
COPD
Primary: Gas Trapping Measured During Washout of the Perfluorinated Gas Mixture. — 0.718; 0.541; 0.308; 0.451 percentage of total lung volume — p=<0.0001
N/A N=12 The Effects of Alcohol Consumption on Central Adiposity
Alcohol Drinking · Weight Loss · Adiposity
Primary: Change in Central (Abdominal) Adiposity — -0.250; -0.071 kg — p=<0.231
Phase 2 N=23 A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
Hypercholesterolemia
Primary: Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15 — -62.48; -8.77; -48.21; -4.93 percent change — p== 0.0009
N/A N=84 Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair
Hernia · Hernia, Abdominal · Hernia, Incisional
Primary: Number of Participants With One or More Surgical Site Occurrence Within 3 Months of Index Procedure — 22 Participants
Phase 3 N=459 Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain
Chronic Low Back Pain
Primary: Change From Baseline to Week 12 in Mean Pain Intensity — 0.6; 1.7 score on a scale
N/A N=137 Informal Caregivers ANSWERS-VA
Stroke · Traumatic Brain Injury
Primary: Caregiver's Depressive Symptoms by Patient Health Questionnaire (PHQ9) Scale — .56; .68; .41; .62 score on a scale — p=.8407
Phase 1 N=16 Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.
Healthy
Primary: Number of Treatment Related Adverse Event, Including Abnormal Laboratory Events — 1; 3; 2; 4 participants
Phase 2 N=169 A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Ovarian Cancer
Primary: Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR) — 11.3; 13.0; 12.2; 6.9 Percentage of Participants
N/A N=72 Psychological Intervention to Reduce Weight Bias Internalization
Stigmatization · Obesity · Weight Loss
Primary: Weight Bias Internalization — -1.3; -1.0 scores on a scale — p=0.22